|Videos|July 17, 2023

Ultra-High Resolution Brain PET: A 'Quantum Leap' for Neuroradiology

Author(s)Jeff Hall

In a recent interview at the SNMMI conference, Roger Lecomte, Ph.D., and Vincent Doyon discussed the advent of ultra-high resolution (UHR) brain positron emission tomography (PET), which reportedly offers double the spatial resolution of conventional PET and may facilitate earlier detection of Alzheimer’s disease and other conditions.

Emphasizing pixelated detectors and an isotropic spatial resolution upward of 1.25 mm, ultra-high resolution (UHR) brain positron emission tomography (PET) represents a significant advance that provides improved characterization and quantification of brain regions that could not be seen with whole-body PET, noted Roger Lecomte, Ph.D., during a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference.

“The spatial resolution is a factor of two better than HRRT (High Resolution Research Tomograph) and a factor of three better than any clinical scanners today. It’s a quantum leap in terms of spatial resolution,” said Dr. Lecomte, a professor of nuclear medicine and radiobiology at the University of Sherbrooke in Quebec, Canada. “To image the brain where you have small structures in the cortex, the brain stem and different regions of the brain, spatial resolution is very important to be able to detect the uptake of radiotracers in very tiny structures.”

One of the areas of improvement with UHR PET imaging was the enhanced visualization of the subfields of the hippocampus that can play a role in the progression of Alzheimer’s disease, according to Vincent Doyon, who presented some of the preliminary findings with UHR PET at the SNMMI conference.

“Depending on how these subfields are affected in the disease, we can see whether treatments are effective for the patient,” added Doyon, a master’s student in the Department of Radiation Sciences and Biomedical Imaging at the University of Sherbrooke.

Donyon added that UHR PET offers enhanced visualization of brainstem nuclei, including raphe nuclei, that may aid in the diagnosis and treatment of a variety of neuropsychiatric conditions, including schizophrenia, depression, and anxiety disorders.

For other insights from Dr. Lecomte and Mr. Doyon, watch the video below.


Related to this article

What CCTA-Based AI Detection of Coronary Inflammation May Reveal About Patients with No Traditional CV Risk Factors
Elevated coronary inflammation, measured with the CCTA-derived and AI-enabled perivascular fat attenuation index (FAI) score, was associated with over a 12-fold higher risk for cardiovascular mortality in patients with no diabetes, hypertension, smoking history or obesity, according to new research presented at the European Society of Cardiology (ESC) Congress.
Foundation Model-Based Chest X-Ray AI Software Gets FDA Nod
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Does kV Still Matter in Photon-Counting CT?
Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.